ArticleBritish journal of pharmacology2018
Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.
Article in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Diels-Alder Adducts of Morphinan-6,8-Dienes and Their Transformations.Molecules (Basel, Switzerland) · 2022Review
- Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.Advances in drug and alcohol research · 2022Article
- The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice.The Journal of pharmacology and experimental therapeutics · 2021Article
- Translational value of non-human primates in opioid research.Experimental neurology · 2021Review
- OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.The Journal of pharmacology and experimental therapeutics · 2020Article
- The aetiology of social deficits within mental health disorders: The role of the immune system and endogenous opioids.Brain, behavior, & immunity - health · 2020Review
- Targeting opioid dysregulation in depression for the development of novel therapeutics.Pharmacology & therapeutics · 2019Review
- Insights into the Neurobiology of Anxiety and a Potential Target for Pharmacotherapy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Article
- Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.British journal of pharmacology · 2018Article
- Emerging areas of opioid pharmacology.British journal of pharmacology · 2018Article
- Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?Neuronal signaling · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeThe κ receptor antagonists have potential for treating neuropsychiatric disorders. We have investigated the in vivo pharmacology of a novel buprenorphine analogue, BU10119, for the first time. EXPERIMENTAL APPROACH: To determine the opioid pharmacology of BU10119 (0.3-3 mg·kg KEY
resultsBU10119 alone was without any antinociceptive activity. BU10119 (1 mg·kg CONCLUSIONS AND IMPLICATIONS: BU10119 is a mixed κ/μ receptor antagonist with relatively short-duration κ antagonist activity. Based on these preclinical data, BU10119 has therapeutic potential for the treatment of depression and other stress-induced conditions. LINKED ARTICLES: This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.